Key points are not available for this paper at this time.
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a complex disorder with an unknown cause. However, the dysbiosis of the gut microbiome has been found to play a role in IBD etiology, including exacerbated immune responses and defective intestinal barrier integrity. The gut microbiome can also be a potential biomarker for several diseases, including IBD. Currently, conventional treatments targeting pro-inflammatory cytokines and pathways in IBD-associated dysbiosis do not yield effective results. Other therapies that directly target the dysbiotic microbiome for effective outcomes are emerging. We review the role of the gut microbiome in health and IBD and its potential as a diagnostic, prognostic, and therapeutic target for IBD. This review also explores emerging therapeutic advancements that target gut microbiome-associated alterations in IBD, such as nanoparticle or encapsulation delivery, fecal microbiota transplantation, nutritional therapies, microbiome/probiotic engineering, phage therapy, mesenchymal stem cells (MSCs), gut proteins, and herbal formulas. FMT, biotics, phage therapy, and other therapies address gut microbiome imbalances and promote eubiosis by fostering the abundance of beneficial microbes.The lower arm signifies increased abundance, whereas the upper arm represents decreased abundance. • The gut microbiota plays a significant role in health and the development of inflammatory bowel disease. • The gut microbiota is a potential biomarker for diagnosing, prognosing, and predicting therapy outcomes in IBD. • Therapies have been shown to regulate the dysbiotic microbiome environment in IBD to promote a state of eubiosis.
Xiu et al. (Mon,) studied this question.